Skip to main content
OpenTrials
Completed

NCT Number: NCT05869422

Low-dose Iron Supplementation in Non-anaemic Iron-deficient Women

The goal of this study is to investigate the efficacy of a low dose iron supplement (6mg) compared to a placebo tablet.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital of Zurich

Zurich, Canton of Zurich, 8091, Switzerland

About this study

The established therapy for iron-deficiency today is oral iron supplementation. However, this often leads to side effects such as constipation, black stools, nausea, and abdominal pain. There are some studies that have compared the efficacy of low-dose iron with normal-dose iron. These showed that the side effects are dose-dependent. Furthermore, some studies have shown that the uptake capacity of high-dose iron is less efficient due to the upregulation of hepcidin. In a pilot study with low-dose iron (6mg per tablet), a significant increase in iron was shown, which can be explained by a lower hepcidin release. Therefore, the investigators would like to show the efficacy of the low-dose iron product in a placebo-controlled setting. Furthermore, the goal is to examine the reduction of side effects before and after administration of the iron and placebo tablet. Additionally, a potential increase of low blood pressure to normal blood pressure will be investigated. There will be two groups of women: one group will be given a low-dose iron supplement of two tablets containing each 6mg for 2 months (60 days), the other one will get two placebo tablet for 2 months, accordingly.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • informed consent as documented by signature
  • female gender
  • premenopausal
  • age > 18 years
  • regular menstrual cycle
  • BMI in normal range (18-25 kg/m²)
  • serum-ferritin ≤30µg/l
  • no anaemia (Hemoglobin ≥117g/l)
  • no intake of dietary supplements containing iron (last 4 weeks)
  • the participant is linguistically and cognitively able to understand the study procedure

Exclusion criteria

  • Current pregnancy
  • breastfeeding
  • hypermenorrhea (more than 5 unties/tampons per day)
  • chronic inflammatory diseases (e.g. colitis)
  • psychiatric disorders
  • chronic kidney disease (creatinine >80 µmol/l)
  • liver disease (ALT >35 U/l)
  • increased CRP (>5mg/l)
  • hypersensitivity to iron-supplements
  • intake of medicines that interact with oral iron supplementation (e.g. PPI)

Treatment and study plan

Iron

Dietary Supplement

60 ± 5 days of daily oral iron supplementation.

Placebo

Other

60 ± 5 days of daily oral placebo intake.

Primary outcomes

  1. Serum-ferritin change

    Time frame: 60 ± 5 days

    significant change of serum-ferritin under supplementation

Secondary outcomes

  1. Blood Pressure

    Time frame: 60 ± 5 days

    change of blood pressure (systolic and diastolic blood pressure)

  2. Blood Sugar

    Time frame: 60 ± 5 days

    change of blood sugar levels

  3. Lipid Status

    Time frame: 60 ± 5 days

    change of lipid status (total cholesterol, HDL, LDL, triglycerides)

Other outcomes

  1. Safety Endpoint

    Time frame: 60 ± 5 days

    Incidence of adverse events during 2 months under low dose iron supplementation and placebo treatment.

Sponsors and collaborators

Lead sponsor

Dr. Krayenbühl GmbH

Industry

Registry information

Official study title

Randomised, Double-blind, Placebo-controlled Clinical Trial Evaluating the Effectiveness of a Low-dose Iron Supplementation in Non-anaemic Iron-deficient Women

Acronym: PCLDIT

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
May 22, 2023
Registry last updated
Jun 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.